Medication info
Valsartan 160 mg Tablet

Valsartan 160 mg Tablet

Prescription medicationTabletOral
Ingredient · strength
Valsartan›160mg / 1 tablet
Manufacturer / importer
Dong-A ST Co., Ltd.
Appearance
Oval film-coated tablet of orange color with a grayish tint
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201100467 · Notified 2011.01.27 · Insurance code 642506480

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this drug at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The antihypertensive effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this drug once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with volume depletion: For patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, start treatment with 40 mg of this drug once daily; do not exceed 80 mg daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this drug orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When administering a diuretic concomitantly, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this drug twice daily; over the following weeks, increase the dose as tolerated by the patient to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment : No dose adjustment is required for creatinine clearance of 10 mL/min or greater. However, do not administer this drug to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment : For patients with mild to moderate hepatic impairment, it is preferable not to exceed a daily dose of 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
1. Essential hypertension: Safety and efficacy have not been established in children and adolescents younger than 18 years. 6. Children: Safety and efficacy have not been established in children and adolescents younger than 18 years.

Ingredients

Manufacturer
Dong-A ST Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
View approved original text

This medication is used to treat essential hypertension and is effective for heart failure patients (NYHA class II to IV) who cannot use ACE inhibitors. It also helps reduce the risk of death in patients with left ventricular dysfunction or reduced contractility after myocardial infarction. Thus, this drug is used not only for blood pressure management but also for heart failure improvement and preventive treatment following myocardial infarction.

How to take

Adult dose

1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this drug at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The antihypertensive effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Start treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this drug once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with volume depletion: For patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, start treatment with 40 mg of this drug once daily; do not exceed 80 mg daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this drug orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When administering a diuretic concomitantly, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this drug twice daily; over the following weeks, increase the dose as tolerated by the patient to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment : No dose adjustment is required for creatinine clearance of 10 mL/min or greater. However, do not administer this drug to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment : For patients with mild to moderate hepatic impairment, it is preferable not to exceed a daily dose of 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

1. Essential hypertension: Safety and efficacy have not been established in children and adolescents younger than 18 years. 6. Children: Safety and efficacy have not been established in children and adolescents younger than 18 years.

Precautions

This drug can cause serious harm to the fetus and newborn when taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant and nursing mothers should not use this medication, and it should not be administered to patients with severe liver disease or significantly impaired kidney function. Due to the strong blood pressure-lowering effect of this medication, caution should be exercised when administering it to the elderly or patients with weakened kidney function, as well as to those with hyperkalemia, and dosage adjustments should be made for patients with impaired liver function. Patients with heart failure or following myocardial infarction may experience changes in kidney function, so regular kidney function tests should be conducted while taking it. There may be a sudden drop in blood pressure during initial use, causing dizziness or fainting; therefore, it is safe to start with a low dose and gradually increase the dose, especially for those on diuretics or who are dehydrated. This medication can increase blood potassium levels, so potassium supplements or potassium-sparing diuretics should be monitored carefully for blood potassium concentration. Concomitant use with non-steroidal anti-inflammatory drugs (NSAIDs) can reduce blood pressure-lowering effects and worsen kidney function; caution is required when using these together. When used with lithium preparations, lithium levels may rise and cause toxicity, so blood lithium concentrations should be frequently checked when used together. This medication contains Yellow No. 5 dye, so patients allergic to this component should use it cautiously. Due to symptoms like dizziness or drowsiness, caution should be taken while driving or operating machinery. In case of overdose, symptoms such as low blood pressure or decreased consciousness may occur, and immediate medical attention is required. The safety and effectiveness of this drug have not been established in children and adolescents, so it is advisable not to use it in this age group. It is important to regularly monitor blood pressure, kidney function, and electrolyte levels to ensure there are no abnormalities during treatment with this medication.

Side effects

  • Headache
  • dizziness
  • viral infection
  • upper respiratory tract infection
  • cough
  • diarrhea
  • fatigue
  • rhinitis
  • sinusitis
  • abdominal pain
Show 53 more
  • stomach ache
  • nausea
  • pharyngitis
  • arthralgia
  • hypotension
  • orthostatic dizziness
  • orthostatic hypotension
  • renal impairment
  • hyperkalemia
  • angioedema
  • edema
  • weakness
  • insomnia
  • erythema
  • decreased libido
  • drowsiness
  • atrial fibrillation
  • vomiting
  • constipation
  • dry mouth
  • anorexia
  • lethargy
  • vascular edema
  • itching
  • serum sickness
  • vasculitis
  • hepatitis
  • syncope
  • epistaxis
  • interstitial pneumonia
  • hypoglycemia
  • shock
  • loss of consciousness
  • rhabdomyolysis
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • bullous dermatitis
  • reduction in red blood cell volume
  • reduction in hemoglobin
  • neutropenia
  • increased serum creatinine
  • increased total bilirubin
  • increased BUN
  • indigestion
  • anemia
  • tinnitus
  • hypertonia
  • exercise intolerance
  • confusion
  • chest pain
  • rash
  • myalgia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is also crucial to store it in a cool place, below 30 degrees Celsius, to maintain the effectiveness of the drug.

Appearance and packaging

Appearance

Oval film-coated tablet of orange color with a grayish tint

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.